BTIG initiated coverage of Akebia Therapeutics (NASDAQ:AKBA) with a “buy” rating and price target of $30. The stock closed at $15.40 on Dec. 6.Read More
Stifel raised its price target for “buy-rated” Reata Pharmaceuticals (NASDAQ:RETA) to $50 from $38 after the company reported statistically significant improvements in kidney function from the Phase 2 portion of its Cardinal study evaluating BARD in Alport chronic kidney disease (CKD). The stock closed at $37.66 on July 24.Read More
Dimerix (ASX:DXB) announced positive safety and efficacy data following a 27-patient Phase 2a proof-of-concept, dose escalation study in chronic kidney disease (CKD) for lead program, DMX-200.Read More
Stifel launched coverage of Reata Pharmaceuticals (NASDAQ:RETA) with a “buy” rating and $38 price target. The stock closed at $23.05 on Feb. 22.Read More
Maxim Group upgraded Keryx Biopharmaceuticals (NASDAQ:KERX) to “buy” from “hold” and reinstated its $7 price target after the FDA approved its application for a second contract manufacturer of Auryxia for the control of serum phosphorus levels in patients with CKD on dialysis.
Shares of Keryx were changing hands at $5.35, up 56 cents, in afternoon trading on Wednesday.Read More